All In Biotech

Drug Trial Radar · NCT05293496

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Apr 19, 2022

Primary completion

Jun 24, 2025

Study completion Aug 26, 2025

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Mar 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .

Conditions

  • Advanced Solid Tumor
  • Castration-Resistant Prostatic Cancer
  • Malignant Melanoma
  • Pancreatic Ductal Carcinoma
  • Hepatocellular Cancer
  • Epithelial Ovarian Cancer
  • Renal Cell Carcinoma

Interventions

  • vobramitamab duocarmazineBiological

    Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

  • lorigerlimabBiological

    Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 2 years
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 2 years
  3. Number of participants with AEs leading to study treatment discontinuationTime frame: Up to 2 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • University of California, San Francisco

    San Francisco, California

  • Florida Cancer Specialists and Research Institute

    Sarasota, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Weill Cornell Medicine

    New York, New York

  • Carolina BioOncology

    Huntersville, North Carolina

  • Stephenson Cancer Center, The University of Oklahoma

    Oklahoma City, Oklahoma

  • University of Pittsburgh Medical Center, Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.